Kestra Private Wealth Services LLC Sells 4,071 Shares of GSK plc (NYSE:GSK)

Kestra Private Wealth Services LLC lowered its holdings in shares of GSK plc (NYSE:GSK) by 23.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,130 shares of the pharmaceutical company’s stock after selling 4,071 shares during the period. Kestra Private Wealth Services LLC’s holdings in GSK were worth $444,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. FMR LLC lifted its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC lifted its stake in shares of GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after buying an additional 51,378 shares in the last quarter. Cerity Partners LLC lifted its stake in shares of GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after buying an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC lifted its stake in shares of GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after buying an additional 83,433 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GSK. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Down 1.0 %

GSK opened at $36.20 on Monday. The company has a quick ratio of 0.53, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a 50 day moving average price of $34.42 and a 200-day moving average price of $37.45. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The stock has a market capitalization of $75.02 billion, a price-to-earnings ratio of 22.76, a PEG ratio of 1.42 and a beta of 0.64.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities research analysts forecast that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.34%. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is currently 93.08%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.